Status:
COMPLETED
Mitral Valve in Hypertrophic Cardiomyopathy
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences
Conditions:
Hypertrophic Obstructive Cardiomyopathy
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of the study is to assess the role of mitral valve apparatus in the development of outflow tract obstruction in patients with hypertrophic cardiomyopathy and to identify the best surgical ...
Detailed Description
It is well-known that mitral valve plays an important role in the development of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. In order to further investigat...
Eligibility Criteria
Inclusion
- Age \>18 years
- Signed informed consent to participate in the study
- For patients with hypertrophic cardiomyopathy only: resting or latent peak left ventricular outflow tract gradient \>50 mmHg, NYHA class III-IV
- For patients with arterial hypertension only: hystory of arterial pressure increase \>140/90 mmHg, increased left vantricular wall thickness (\>10 mm) and myocardial mass indexed to BSA (\>95 g/m2 for women and \>115 g/m2 for men), as assessed by 2D transthoracic echocardiography
Exclusion
- Age \< 18 years
- Persistent form of atrial fibrillation
- Intrinsic mitral or aortic valve disease
- Coronary artery disease
- Reduced left ventricular ejection fraction
- For control group only: presence of any structural heart disease
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03877731
Start Date
December 1 2006
End Date
September 1 2019
Last Update
January 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiology research institute, National Research Medical Center of the Russian Academy of Sciences
Tomsk, Russia, 634012